0001293577-18-000003.txt : 20180112
0001293577-18-000003.hdr.sgml : 20180112
20180112152144
ACCESSION NUMBER: 0001293577-18-000003
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180110
FILED AS OF DATE: 20180112
DATE AS OF CHANGE: 20180112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Katz Richard D
CENTRAL INDEX KEY: 0001293577
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35443
FILM NUMBER: 18525831
MAIL ADDRESS:
STREET 1: 4505 EMPEROR BOULEVARD
STREET 2: SUITE 300
CITY: DURHAM
STATE: NC
ZIP: 27703
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARGOS THERAPEUTICS INC
CENTRAL INDEX KEY: 0001105533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 562110007
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4233 TECHNOLOGY DR
CITY: DURHAM
STATE: NC
ZIP: 27704
BUSINESS PHONE: 9192876300
MAIL ADDRESS:
STREET 1: 4233 TECHNOLOGY DR
CITY: DURHAM
STATE: NC
ZIP: 27704
FORMER COMPANY:
FORMER CONFORMED NAME: MERIX BIOSCIENCE INC
DATE OF NAME CHANGE: 20000207
4/A
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4/A
2018-01-10
2018-01-12
0
0001105533
ARGOS THERAPEUTICS INC
ARGS
0001293577
Katz Richard D
4505 EMPEROR BOULEVARD
SUITE 300
DURHAM
NC
27703
0
1
0
0
Vice President and CFO
Common Stock
2018-01-10
4
S
0
104435
0.1647
D
193959
D
Shares reported represent an amount sold to cover the tax liabilities of the reporting person pursuant to a 10b5-1 sales instruction related to a restricted stock award agreement dated August 30, 2017. Acquisition of the restricted stock was previously reported in Table I of the reporting person's Form 4 on August 31, 2017.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.1621 to $0.1683 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the
range set forth in this footnote.
Inadvertently filed with incorrect transaction date of 1/9/2018. Transaction occurred on 1/10/2018.
/s/ Lori R. Harrelson, attorney-in-fact
2018-01-12